Chan, EWW;
Leung, MTY;
Lau, LKW;
Leung, J;
Lum, D;
Wong, RS-M;
Li, X;
... Lai, FTT; + view all
(2022)
Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: a prospective cohort study.
International Journal of Infectious Diseases
10.1016/j.ijid.2021.12.354.
(In press).
Preview |
Text
1-s2.0-S1201971221012534-main.pdf - Accepted Version Download (494kB) | Preview |
Abstract
Objectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the Covid-19 infection, extant research in adverse reactions using real-world data of various socio-demographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from generalized mixed model showed that compared with adults aged 18 – 59, older adults aged 60 or above had a lower risk of adverse reactions, and adolescents aged 12 – 17 had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated.
Type: | Article |
---|---|
Title: | Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: a prospective cohort study |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.ijid.2021.12.354 |
Publisher version: | https://doi.org/10.1016/j.ijid.2021.12.354 |
Language: | English |
Additional information: | © 2022 Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0/) |
Keywords: | Covid-19, vaccine safety, pharmacovigilance, epidemiology, paediatrics |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
URI: | https://discovery.ucl.ac.uk/id/eprint/10141444 |
Archive Staff Only
View Item |